Drug Profile
Research programme: interleukin-1 receptor associated kinase 4 inhibitors - Nimbus Therapeutics
Alternative Names: IRAK4 inhibitors - Nimbus Therapeutics; ND-2110; ND-2158; ND-346Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Nimbus Discovery
- Developer Nimbus Therapeutics
- Class Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Haematological malignancies; Rheumatic disorders
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Rheumatic-disorders in USA (Parenteral)